Clinical Trials

60 enrolled

Other hematologic neoplasm

Lymphoma, Recurrence

NCT04749355 2023-03-09

Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS

Phase 2 Unknown

40 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT04933825 2023-02-17

A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)

Phase NA Unknown

18 enrolled

Recurrence

NCT05727683 2023-02-14

CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

33 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

Phase 3 Unknown

368 enrolled

Recurrence

NCT05693831 2023-01-23

myCare-102

730 enrolled

Neoplasms, Recurrence

NCT05007418 2023-01-17

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

54 enrolled

Multiple Myeloma, Recurrence

NCT05557903 2022-09-28

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

71 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, T-Cell

NCT05150457 2022-09-27

Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors

48 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT04962529 2022-08-11

Breast Cancer Liquid Biopsy Trial

450 enrolled

Breast

Breast Neoplasms, Neoplasms, Recurrence

NCT04861779 2022-08-03

A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies

156 enrolled

Recurrence

NCT05212584 2022-07-06

CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma

LymphoidOther hematologic neoplasm

24 enrolled

Leukemia, Recurrence, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05426798 2022-06-22

Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

MyeloidOther hematologic neoplasm

73 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT05155839 2022-02-22

Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

108 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT05236621 2022-02-11

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 3 Unknown

85 enrolled

Multiple Myeloma, Recurrence

NCT05223686 2022-02-04

To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.

LymphoidOther hematologic neoplasm

18 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05052970 2022-02-01

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

60 enrolled

Multiple Myeloma, Recurrence

NCT05100303 2021-10-29

A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)

Other hematologic neoplasm

58 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT04948788 2021-09-28

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Phase 2 Unknown

102 enrolled

Recurrence, Lymphoma, B-Cell

NCT04689308 2021-09-08

This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies

57 enrolled

Recurrence

NCT04458389 2021-08-13

A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

268 enrolled

Lymphoma, Recurrence

NCT04984434 2021-07-30

Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma

68 enrolled

Multiple Myeloma, Recurrence

NCT02785250 2021-06-18

Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

85 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasms, Recurrence

NCT04003168 2021-03-01

Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma

18 enrolled

Multiple Myeloma, Recurrence

NCT03265106 2021-02-04

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects

20 enrolled

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell

NCT04204161 2021-02-04

A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

30 enrolled

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell

NCT04108325 2021-01-28

A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

58 enrolled

Phase EARLY_PHASE1 Unknown

Recurrence, Lymphoma, T-Cell, Peripheral

NCT04626752 2020-11-13

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

50 enrolled

Multiple Myeloma, Recurrence

NCT04623333 2020-11-10

A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer

Phase 2 Unknown

80 enrolled

Gynecologic

Uterine Cervical Neoplasms, Recurrence

NCT03825146 2020-02-24

AMPCAL

Other hematologic neoplasm

10 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT02387879 2019-09-26

A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR

500 enrolled

Multiple Myeloma, Recurrence

NCT04056975 2019-08-14

A-319

54 enrolled

Recurrence, Lymphoma, B-Cell

NCT01211457 2019-07-16

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

MyeloidOther hematologic neoplasm

65 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT00772317 2019-04-10

STAR

Phase NA Unknown

117 enrolled

Genitourinary

Prostatic Neoplasms, Recurrence

NCT03000335 2019-02-04

Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk

65 enrolled